Galenica AG/Fr. GALE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Galenica AG
Galenica AG operates within the healthcare sector, focusing on pharmaceutical distribution, retail, and services in Switzerland. Its core business includes the distribution of medicines and health products, operating one of the largest pharmacy networks, and providing specialized healthcare logistics and digital services. Founded in 1927 and headquartered in Bern, Switzerland, Galenica leverages its extensive network and partnerships to maintain a strong presence in the Swiss market. The company is strategically positioned through its integration across the pharmaceutical supply chain, offering a comprehensive range of products and services to improve healthcare accessibility and efficiency.
- Ticker
- Fr. GALE
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 6,623
- Headquarters
- Bern, Switzerland
- Website
- www.galenica.com
Galenica AG Metrics
BasicAdvanced
CHF 4.4B
27.57
CHF 3.19
0.28
CHF 2.50
1.42%
Price and volume
Market cap
CHF 4.4B
Beta
0.28
52-week high
CHF 103.00
52-week low
CHF 80.30
Average daily volume
88K
Dividend rate
CHF 2.50
Financial strength
Current ratio
1.07
Quick ratio
0.642
Long term debt to equity
0.54
Total debt to equity
0.783
Dividend payout ratio (TTM)
78.72%
Interest coverage (TTM)
13.90%
Profitability
EBITDA (TTM)
255.693
Gross margin (TTM)
12.46%
Net profit margin (TTM)
3.71%
Operating margin (TTM)
4.77%
Effective tax rate (TTM)
17.18%
Revenue per employee (TTM)
CHF 650,000
Management effectiveness
Return on assets (TTM)
4.00%
Return on equity (TTM)
11.36%
Valuation
Price to earnings (TTM)
27.574
Price to revenue (TTM)
1.023
Price to book
3.1
Price to tangible book (TTM)
-245
Price to free cash flow (TTM)
22.941
Free cash flow yield (TTM)
4.36%
Free cash flow per share (TTM)
3.832
Dividend yield (TTM)
2.84%
Forward dividend yield
1.42%
Growth
Revenue change (TTM)
6.39%
Earnings per share change (TTM)
-17.39%
3-year revenue growth (CAGR)
5.09%
3-year earnings per share growth (CAGR)
-16.06%
3-year dividend per share growth (CAGR)
4.35%
What the Analysts think about Galenica AG
Analyst ratings (Buy, Hold, Sell) for Galenica AG stock.
Analyst projections of the future price of Galenica AG stock.
Bulls say / Bears say
First-half sales rose 7.1% to CHF 2,136.5 million and adjusted EBIT rose 7.1%; excluding a prior-year one-off, EBIT growth was 12.6%. Galenica reaffirmed 2026 guidance for 5–7% sales growth and 6–8% adjusted EBIT growth. (Galenica)
Galenica’s pharmacy business grew 6.2% in the first half, with 4.3% organic growth, outperforming the market after allowing for product mix. Paid pharmacy consultations also rose 27% to 193,000, showing growing demand for services beyond medicine sales. (Galenica)
Wholesale sales increased 4.3% in the first half, while the recently added diagnostics business generated CHF 62.2 million in sales. Growth across distribution and diagnostics gives Galenica more than one route to expand beyond its retail pharmacy network. (Galenica)
Products & Brands sales fell 9.8% in the first half. A mild cold-and-flu season hurt its seasonal portfolio, while continued Perskindol inventory reductions after an EU regulatory change weighed on international sales. (Galenica)
Swiss cost-containment measures cut laboratory handling fees by CHF 5 and prices for the ten highest-revenue tests by 10%. These reimbursement changes may pressure economics in diagnostics, one of Galenica’s newer growth areas. (Investing.com)
Bichsel plans to close its pharmaceutical production division by the end of 2026 because the specialist business is not competitive; the closure may affect up to 170 jobs and carries around CHF 30 million in one-off costs. The expected annual EBIT benefit after closure is only around CHF 3 million. (Galenica)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
Galenica AG Financial Performance
Revenues and expenses
Galenica AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Galenica AG
AllUSDEUR
Fund name | Fund size | Fr. GALE weighting |
|---|---|---|
iShares MSCI World Small Cap£WLDS | $9B | 0.05% |
iShares MSCI World Small Cap€IUSN | $9B | 0.05% |
iShares MSCI World Small Cap$WSML | $9B | 0.05% |
iShares STOXX Europe 600€EXSA | €9.7B | 0.04% |
iShares STOXX Europe 600€EXIE | €904M | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.